Integrated Wealth Concepts LLC lowered its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 66.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,279 shares of the company’s stock after selling 31,992 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in AstraZeneca were worth $1,130,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of AZN. ICA Group Wealth Management LLC purchased a new position in AstraZeneca in the fourth quarter valued at about $26,000. Parkside Financial Bank & Trust lifted its position in shares of AstraZeneca by 4,875.0% in the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after buying an additional 390 shares during the last quarter. Fairfield Bush & CO. acquired a new stake in shares of AstraZeneca in the first quarter worth about $28,000. Red Tortoise LLC acquired a new stake in shares of AstraZeneca in the fourth quarter worth about $30,000. Finally, Byrne Asset Management LLC lifted its position in shares of AstraZeneca by 55.0% in the fourth quarter. Byrne Asset Management LLC now owns 465 shares of the company’s stock worth $32,000 after buying an additional 165 shares during the last quarter. Hedge funds and other institutional investors own 16.07% of the company’s stock.
AstraZeneca Trading Up 4.7 %
AstraZeneca stock opened at $71.33 on Monday. The business has a 50 day moving average price of $70.68 and a two-hundred day moving average price of $70.23. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.75. The stock has a market cap of $221.11 billion, a price-to-earnings ratio of 35.84, a price-to-earnings-growth ratio of 1.45 and a beta of 0.50. AstraZeneca PLC has a 12 month low of $52.65 and a 12 month high of $76.56.
Analysts Set New Price Targets
A number of analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, July 12th. StockNews.com assumed coverage on AstraZeneca in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. Morgan Stanley raised AstraZeneca from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, April 11th. Finally, HSBC assumed coverage on AstraZeneca in a research report on Friday, July 14th. They set a “buy” rating for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $103.00.
AstraZeneca Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Featured Articles
- Five stocks we like better than AstraZeneca
- The Dividend Kings With Highest Yield
- Should a Lack of Windfall Profits Keep You Out on Chevron Stock?
- Why Invest in High-Yield Dividend Stocks?
- Two Foolproof Plays for Apple’s Earnings
- Insider Trading – What You Need to Know
- MarketBeat Week in Review – 7/24 – 7/28
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
